Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rated “Buy” in New Coverage at Craig Hallum

Stock analysts at Craig Hallum initiated coverage on shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) in a report issued on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. Craig Hallum‘s price target points to a potential upside of 376.19% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Canaccord Genuity Group began coverage on Quoin Pharmaceuticals in a report on Monday, October 19th. They issued a “buy” rating and a $18.00 price objective for the company. Weiss Ratings raised Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, November 12th. Lake Street Capital began coverage on Quoin Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen lowered Quoin Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 15th. Finally, BTIG Research assumed coverage on Quoin Pharmaceuticals in a research report on Monday, October 12th. They set a “buy” rating and a $14.00 price target on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Get Our Latest Research Report on QNRX

Quoin Pharmaceuticals Price Performance

Shares of QNRX stock opened at $3.36 on Friday. Quoin Pharmaceuticals has a 12 month low of $3.25 and a 12 month high of $23.50. The company’s fifty day simple moving average is $4.71 and its 200-day simple moving average is $5.69.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.52) by $0.55. As a group, sell-side analysts forecast that Quoin Pharmaceuticals will post -7.45 EPS for the current year.

Insider Activity

In other news, CEO Michael Myers bought 20,490 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $4.88 per share, for a total transaction of $99,991.20. Following the purchase, the chief executive officer owned 37,713 shares of the company’s stock, valued at approximately $184,039.44. This trade represents a 118.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sally Lawlor bought 10,244 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was purchased at an average price of $4.88 per share, with a total value of $49,990.72. Following the completion of the purchase, the chief financial officer directly owned 10,684 shares in the company, valued at $52,137.92. The trade was a 2,328.18% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 57,370 shares of company stock valued at $279,966 over the last quarter. 7.54% of the stock is currently owned by company insiders.

Institutional Trading of Quoin Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of QNRX. SummitTX Capital L.P. lifted its position in shares of Quoin Pharmaceuticals by 54.8% in the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock valued at $662,000 after buying an additional 35,505 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Quoin Pharmaceuticals during the 3rd quarter worth approximately $1,077,000. Finally, AIGH Capital Management LLC boosted its stake in shares of Quoin Pharmaceuticals by 237.5% during the 3rd quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock worth $1,077,000 after acquiring an additional 166,234 shares during the period. Institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

(Get Free Report)

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

Further Reading

Analyst Recommendations for Quoin Pharmaceuticals (NASDAQ:QNRX)

Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.